Martin Pretty

"If a strategic investor buys new shares in a microcap at a premium and no one cares, does the deal impact on value?" That's the variation on the old "If a tree falls in a forest..." thought experiment that came to mind following a couple of recent deals. Show More

Mark Tobin

MedAdvisor (MDR: ASX) operates in the healthcare IT space, specifically in improving the interaction between pharmacies, patients, drug manufacturers, doctors, and government. MDR provides a fully digital end to end experience for handling medical scripts for prescribed medication, primarily targeting chronic conditions which require ongoing medication management. Show More

Livewire Exclusive

A swathe of microcaps put in some truly remarkable gains last year. The share prices of Bubs, Jervois, and MyFiziq increased 12, 16, and 30 times respectively, and there were scores more that tripled or quadrupled. Yet many of these stocks have business models at very early, or even conceptual,... Show More


CommSec’s Tom Piotrowski speaks with MedAdvisor (MDR) CEO, Rob Read about the company’s new distribution partner Arrow Pharmaceuticals To view more Executive Series interviews, visit: Show More